SRSF3 and cancer: These variants can confer drug resistance even if they are not as effective as the full-length MRP1. Further study found that SRSF3 overexpressed in ovarian tumors could result in more splicing variants of MRP1 mRNA by increasing the identification of weak exons (26), which indicates that SRSF3 may be involved in the cancer chemotherapy resistance.